ClinicalTrials.gg
Not yet recruitingNCT07573501Updated May 11, 2026

Dual-site Cross-frequency Coupled Transcranial Electrical Stimulation Modulates Working Memory of Patients With Post-stroke Cognitive Impairment

An interventional study of occupational therapy and real tACS in Stroke and Cognition Disorders, sponsored by Ke Dong, MD. Not yet recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Ke Dong, MD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
400th of 432
24 · median 169
Started
2026
with 65 others
No phase
264 of 613
123 open now
Primary completion
2027-05
later than 161 of 262 live
Registered
564th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 400th largest by planned enrollment of the 432 interventional ones that give a count, is one of 66 that started in 2026, is one of 264 with no phase, reaches primary completion later than 161 of the 262 other live ones, and was the 564th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

This clinical trial aims to explore the effect of dual-site theta-gamma cross-frequency coupled transcranial alternating current stimulation in the frontal and parietal region on the working memory ability of patients with cognitive impairment after stroke, and to evaluate the safety of this protocol. The main purpose is to answer the following question: Can dual-site cross-frequency coupled tACS in the frontal parietal region improve the performance of working memory and cognitive-motor dual tasks in stroke patients? What is its mechanism of action? Researchers will compare the effects of real cross-frequency coupled stimuli and sham stimuli to see if the real stimuli can bring better results to patients. Participants will receive 40 minutes of real or sham electrical stimulation once a day for 5 consecutive days. Clinical evaluations (cognitive scales) and fNIRS were conducted respectively before and after stimulation to record the relevant brain activities at rest and during cognitive tasks

03

Conditions studied

  • Stroke
  • Cognition Disorders
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meeting the diagnostic criteria for hemorrhagic or ischemic stroke in the Chinese Guidelines for the Prevention and Treatment of Cerebrovascular Diseases(2nd edition), with the first onset, single hemisphere stroke, and confirmed by CT or MRI,course of diease 1-6 months;
  • Age ranging from 30 to 80 years old;
  • Native language is Mandarin or Cantonese;
  • Right-handed;
  • Diagnosed with PSCI by the scale;
  • Able to cooperate in completing the speech repetition test;
  • Normal hearing.

Exclusion criteria

Exclusion Criteria:

  • Currently receiving non-invasive brain stimulation treatment;
  • Lesions involving the left DLPFC brain regions;
  • History of epilepsy, mental illness,or other neurological or mental disorders;
  • Any for transcranial electrical stimulation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    real tACS

    Behavioral: occupational therapy · Other: real tACS

  • Sham comparator
    sham tACS

    Behavioral: occupational therapy · Other: sham tACS

Interventions

  • Behavioraloccupational therapy

    occupational therapy (especially cognitive therapy) 40min a day for 5 days

  • Otherreal tACS

    real theta-gamma CFC tACS for 40min a day for 5 days during cognitive therapy

  • Othersham tACS

    sham theta-gamma CFC tACS for 40min a day for 5 days during cognitive therapy

06

What researchers measure

Primary outcomes

  1. n-back task accuracy rate

    n-back task record accuracy rate

    Time frame: Baseline and 5-days

  2. n-back task reaction time

    n-back task record reaction time

    Time frame: Baseline and 5-days

  3. function connectivity during n-back task

    n-back task with fNIRS to record Oxy-Hb Concentration

    Time frame: Baseline and 5-days

  4. Verbal fluency test(VFT)accuracy rate

    VFT task record accuracy rate

    Time frame: Baseline and 5-days

  5. Verbal fluency test(VFT)reaction time

    VFT task record reaction time

    Time frame: Baseline and 5-days

  6. function connectivity during Verbal fluency test(VFT)

    VFT task with fNIRS to record Oxy-Hb Concentration

    Time frame: Baseline and 5-days

Secondary outcomes

  1. Montreal Cognitive Assessment(MoCA)

    MoCA scale(score 0-30, the higher score means the better function)

    Time frame: Baseline and 5-days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2027, 12 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 12 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 7, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07573501
Lead sponsor
Ke Dong, MD
Responsible party
Ke Dong, MD (Principal Investigator, First Affiliated Hospital, Sun Yat-Sen University) — Sponsor-investigator
First posted
May 7, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
May 11, 2026

Study contacts

Jingting Li
Contact
lijt53@mail.sysu.edu.cn
+86 13560365827
Hanjun Liu
Contact
lhanjun@mail.sysu.edu.cn
+86 15920175118

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion